Introduction: Available methods, including serum thyroglobulin (Tg) measurement and whole-body scan (WBS) performed after radioiodine administration, allow for a precise diagnostics in differentiated thyroid cancer (DTC). However, some asymptomatic patients demonstrate negative WBS despite a high Tg serum concentration. In these subjects, fluorodeoxyglucose-positron emission tomography (FDG-PET) should be considered. The primary aim of our study was to evaluate a diagnostic value of FDG-PET in asymptomatic hyperthyroglobulinemia. The secondary one was to determine a prognostic value of a negative FDG-PET result in DTC patients with elevated Tg level. Material: One hundred and ten FDG-PET/CT scans were retrospectively analyzed, 85 scans were done under TSH stimulation and 25 on LT 4 suppressive therapy. Follow-up ranged between 4 and 9 years. Results: The first FDG-PET/CT detected cancer foci in 49 subjects with a global sensitivity of 45%. When the sensitivity was evaluated with reference to TSH stimulation and suppression, its values were 50 and 28% respectively. In 42 patients, FDG-PET failed to diagnose the reason for elevated Tg level. During further follow-up, in 17 of them, DTC recurrence was detected by other methods (CT, MRI, US). Fourteen subjects with asymptomatic hyperthyroglobulinemia were free of DTC progression for at least 4 years. Conclusions: FDG-PET in DTC patients with asymptomatic hyperthyroglobulinemia constitutes a valuable diagnostic tool. Negative FDG-PET demonstrated a limited prognostic significance, as only every third patient did not show DTC progression. Moreover, negative FDG-PET does not justify less strict DTC monitoring, because it is related to 40% risk of relapse during the 5-year follow-up.
Introduction
Differentiated thyroid cancer (DTC) is generally characterized by a good prognosis and long-term course of the disease. Available methods allow for a precise diagnostics and effective treatment in most DTC patients (1, 2) . Serum thyroglobulin (Tg), a protein produced by both normal thyroid follicular cells and DTC cells, constitutes a very useful DTC marker. In patients who underwent total thyroidectomy and complementary radioiodine (RAI) treatment, the only source of thyroglobulin are DTC cells (3) . Moreover, DTC cells show the ability of iodine uptake. This feature enables the use of RAI for DCT diagnostics and treatment (4, 5) . However, in some patients, DTC cells do not demonstrate iodine uptake. In such cases, the sensitivity of whole-body scan (WBS), performed after RAI administration, is insufficient to localize cancer foci despite a high serum Tg concentration. It concerns mostly asymptomatic patients, without clinically apparent disease and no abnormalities in imaging studies, in whom a rise in serum Tg level is the only signal of DTC progression (asymptomatic hyperthyroglobulinemia). Early detection of DTC relapse in these patients significantly increases the possibility of an effective treatment, especially in a case of local recurrence or single metastases amendable for surgery. In a patient with elevated serum Tg level, negative WBS and normal results of imaging studies fluorodeoxyglucose-positron emission tomography (FDG-PET) may be considered (6, 7, 8) . It is in fact an examination dedicated for the diagnostics of other types of cancer that, in contrary to DTC, show a high dynamics and rapid cell divisions. However, loss of the ability of RAI uptake by DTC cells may be a signal of a partial cancer dedifferentiation. Additionally, some DTC subtypes are characterized by a more aggressive course of the disease, observed from its onset (9, 10) . In such cells, glucose metabolism is increased, which results in a higher and more intense FDG uptake in cancer foci than in normal tissues and enables cancer localization (11) . Positive FDG-PET result has a negative prognostic significance, while the value of a negative FDG-PET scan in patients with isolated hyperthyroglobulinemia is unclear.
Asymptomatic hyperthyroglobulinemia in DTC patients after primary treatment, involving total thyroidectomy and complementary RAI therapy, constitutes an unquestionable indication for FDG-PET. However, the conditions under which PET/Ct should be done are yet to be established. Hormonal status is particularly important in DTC diagnostics. It is believed that TSH stimulates glucose uptake by an increase in GLUT expression in cellular membrane and glycolysis stimulation. According to some authors, TSH increase may improve the sensitivity of FDG-PET (9, 12) . It is believed that endo-and exogenous TSH stimulation gives similar outcomes (13) .
Though there are no doubts regarding the need of FDG-PET in patients with asymptomatic hyperthyroglobulinemia, the value of Tg cut-off level that should indicate FDG-PET is still discussed. The most often recommended Tg value is 10 ng/mL (14, 15) . However, any detectable Tg level may be worrying. Recently, the role of dynamic changes in serum Tg concentration is particularly emphasized.
FDG-PET is recommended when Tg doubling time is shorter than 1 year (16) . Noteworthy, the role of FDG-PET in DTC is not confined to asymptomatic Tg increase. Its prognostic value as well as the usefulness in DTC follow-up is also emphasized (17) . Although previous studies have reported sufficient FDG-PET sensitivity, in real clinical practice the results are often disappointing. Thus, our report considers the sensitivity of FDG-PET in real practice.
Thus, the aim of our study was rather to evaluate the usefulness of a widely accepted method in a real clinical practice than the exact diagnostic value of FDG-PET in DTC patients with elevated serum Tg level. We also tried to determine a prognostic value of a negative FDG-PET result in DTC patients with elevated Tg level.
Subjects and methods
The study involves 92 DTC patients, 55 women and 37 men in whom 110 FDG-PET examinations, performed between 2006 and 2011, were done to localize the source No patient presented distant metastases at DTC diagnosis. All subjects underwent primary treatment involving total thyroidectomy and complementary RAI therapy. Therapeutic RAI activities ranged between 60 and 100 mCi and no patient demonstrated RAI uptake outside thyroid bed in posttherapeutic WBS. The patients were subjected to DTC monitoring due to asymptomatic elevated serum Tg level. Nobody showed DTC recurrence or distant metastases on WBS or in systematically repeated different imaging studies. Duration of the further follow-up after FDG-PET examination was 4-9 years -most often 6 years ( Table 2) . During this period, subsequent imaging studies, including FDG-PET, were performed. Noteworthy, in 13 patients, FDG-PET was repeated several times. Twenty-five FDG-PETs were done under TSH suppression and 85 under TSH stimulation, of them 46 with the use of recombined thyrotropin α (rhTSH) (exogenous stimulation). These examinations done under TSH suppression were prompted either by consecutively increasing Tg level or by previous statement of Tg > 10 ng/mL at the TSH stimulation. Detectable serum Tg level and prolonged hyperthyroglobulinemia, especially increasing Tg concentrations, constituted the indications for FDG-PET (Table 3) .
At the beginning, serum Tg concentration was measured by Trace (Timed Resolved AMplified Cryptate Emission) method (BRAHMS Aktiengeselschaft, Kryptor). Next, ECLIA (ElectroChemiluminescent Immuno Assay) method (Roche diagnostic, Cobas e411) was used. The analytic sensitivities of both methods were 0.17 and 0.1 ng/mL, whereas functional sensitivities were 0.5 and 1 ng/mL respectively.
PET combined with computed tomography (PET/ CT hybrid scanner Philips GEMINI GXL) was performed 60 min after intravenous administration of 7.4 mCi of 18 flourodeoxyglucose ( 18 FDG). The scanning volume covered the area from the top of the skull to the middle of the thighs. The reconstruction was made in three basic planes after correction for attenuation based on CT examination. CT scan was performed in the spiral mode, without intravenous contrast administration, with images reconstructed every 3 mm.
Locoregional neck abnormalities have always been verified by neck US. If it was possible (when the recurrent tumor was visualized), FNAB was carried out to confirm DTC recurrence. If necessary, in a case of distant metastases with tracer uptake on FDG-PET, additional CT or MRI have been done. All patients were negative at WBS, performed before FDG-PET.
Statistical analysis was carried out using STATISTICA software, version 10 (2011; StatSoft, Inc; USA and Stata 13.1 for Windows). Comparison between the groups was performed using Yates' chi-square test or Fisher's exact test; P value <0.05 was considered as significant.
Results
Forty-nine FDG-PETs (45%) detected cancer foci, 3 (2%) examinations gave an equivocal result, whereas in 58 remaining FDG-PETs (53%), no pathological tracer uptake was noticed. The sensitivity of FDG-PET, carried out under TSH suppression, was 28%, whereas, when the examination was performed after TSH stimulation, it was 50% (P = 0.069; Fisher's exact test) (Table 4) . When FDG-PET was done under TSH stimulation, its sensitivity did not differ significantly regarding the way of TSH stimulation (endogenous or exogenous). These values for endogenous and exogenous TSH stimulation were 54 and 46% respectively (P = 0.592) ( Table 5 ).
The change in the cut-off value of serum Tg level, which constituted an indication for FDG-PET, influenced its sensitivity. When we used Tg cut-off value of 10 ng/mL, measured in patients under TSH suppression, the obtained FDG-PET sensitivity was 68% (Table 6 ). Among 31 patients in whom serum Tg level, measured under TSH suppression, was >10 ng/mL, FDG-PET performed under TSH stimulation allowed for the detection of Tg source in 19 subjects with a sensitivity of 73%.
The sensitivity of FDG-PET differs depending on histopathological cancer subtype (P = 0.049), especially when FDG-PET was performed after TSH stimulation (P = 0.005) ( Table 7) . The global sensitivity of FDG-PET, carried out in a subgroup of patients with papillary thyroid carcinoma, was 37% (27% when FDG-PET was performed under TSH suppression and 40% after TSH stimulation). Considering follicular thyroid cancer, the global sensitivity was 70%, for studies done under TSH suppression and stimulation 25 and 92% respectively. The differences were statistically significant (P = 0.025 for the whole groups and P = 0.002 when FDG-PET was done after TSH stimulation). Considering oxyphilic and poorly differentiated thyroid cancer, the sensitivity of FDG-PET was 67 and 33% respectively.
A group of 42 subjects, in whom FDG-PET did not localize DTC foci, was observed during the next 4-9 years. The analysis involved all patients, regardless of Tg and TSH concentration at FDG-PET. In 17 of them (40%), DTC progression was diagnosed and new cancer foci were visualized by subsequent imaging studies. In eight patients, locoregional recurrence, found in neck ultrasound (US), was confirmed by the fine needle aspiration biopsy (FNAB). In four other patients, mediastinal lymph nodes or bone metastases were detected by another FDG-PET, performed 1-3 years later, and in two lung and bone metastases were observed in posttherapeutic WBS, done after RAI treatment due to persistent hyperthyroglobulinemia following FDG-PET. However, in the remaining three patients, mediastinal or lung metastases were diagnosed by CT scan. Eleven (26%) of these 42 subjects demonstrated small lung nodules of clinically undetermined significance and 14 (33%) were free of disease for a median period of 5.5 years. Mean serum Tg level for the whole group of 42 patients was 6.25 ± 2.8 ng/mL, when measured by TSH suppression and 15 ± 6.6 ng/mL after TSH stimulation, median values were 6.9 and 15.0 ng/mL respectively.
Discussion
FDG-PET is routinely used in oncology, especially for the evaluation of disease stage and the course of highly aggressive neoplasms. Its diagnostic value is related to its high sensitivity. DTC, characterized by an indolent nature, may not be a good 'candidate' for such diagnostics. Nevertheless, currently, FDG-PET has been widely accepted in DTC diagnostics, particularly in patients without clinical evidences of the disease and with a negative WBS after RAI administration, in whom the only symptom of DTC progression is asymptomatic hyperthyroglobulinemia. However, the data related to FDG-PET sensitivity vary Table 5 The results of FDG-PET depending on the way of TSH stimulation. (20) . Similar data, reported by Caetano et al. in 2015, was obtained from a meta-analysis evaluating the sensitivity and specificity of FDG-PET/CT in the detection of DTC recurrences to be 93 and 81% respectively (21) . The sensitivity of FDG-PET/CT in our study was relatively low probably because some enrolled patients showed only a slight increase in serum Tg level. We are aware that the evaluation of the diagnostic value of PET/CT is an old issue, better analyzed by previous studies and that our results in terms of FDG-PET sensitivity are not in line with the literature. However, we should emphasize that our study was not in fact aimed to evaluate the sensitivity of FDG-PET and to perform a prognostic analysis. We rather focused on the clinical usefulness of a widely accepted method in the real clinical practice. According to the published data and our own analysis, a positive FDG-PET result was achieved in DTC patients with higher serum Tg level (18, 22) . When Tg cut-off level that constitutes an indication for FDG-PET is lower, the sensitivity of FDG-PET decreases as a larger tumor volume is related to the higher Tg level and simultaneously the larger tumor is easier to detect. The choice of an appropriate Tg cut-off value for FDG-PET, in DTC patients with asymptomatic hyperthyroglobulinemia, results in a better accuracy of FDG-PET. We are aware that the Tg cutoff value, proposed by the ATA guidelines, is not always confirmed in the daily practice (14) . The low sensitivity observed in our study also reflects that higher Tg value may be required to achieve a better accuracy of FDG-PET.
Results of FDG-PET
Some authors recommend Tg value of 10 ng/mL, measured under TSH suppression (15) , whereas others, including ATA guidelines, recommend Tg 10 ng/mL, measured under TSH stimulation. In our study, we evaluated the Tg cut-off value under TSH suppression, because most Tg evaluations are carried out during L-T4 administration in the majority of our patients.
Another important issue that should be considered with reference to FDG-PET in DTC subjects is the hormonal status when FDG-PET is performed. Wang et al., in a paper published in 1999, did not report any improvement in the detection of DTC foci after TSH stimulation (9). However, Moog et al. suggest carrying out FDG-PET under TSH stimulation, as according to them glucose uptake by DTC cells depends on serum TSH concentration (23) . Similarly, Chin et al., in a small series of DTC patients, confirmed the beneficial effect of TSH stimulation on the FDG-PET results (24) . Moreover, the meta-analysis of Ma et al. also demonstrated a positive impact of TSH stimulation on the sensitivity of FDG-PET. On the other hand, Leboulleux et al. found more DTC foci after rhTSH stimulation although they did not observe any increase in the number of positive FDG-PETs comparing with negative ones with reference to TSH stimulation (13) . Hormonal stimulation in our study improved PET-FDG sensitivity and when the criterion of Tg cut-off value of 10 ng/mL in patients qualified for FDG-PET was used, the sensitivity was 73%.
The differences in the sensitivity of FDG-PET according to histological subtype of thyroid cancer are interesting. It points a higher sensitivity of FDG-PET in follicular thyroid carcinoma. Noteworthy, the most aggressive cancer in analyzed group -poorly differentiated thyroid carcinoma -was related to much lower FDG-PET sensitivity. However, the PDTC subgroup was very small, so further studies are required.
Even under the most optimal conditions, there are some patients in whom FDG-PET gives a negative result despite the elevated serum Tg level. Therefore, we asked the question whether negative FDG-PET in a patient with asymptomatic hyperthyroglobulinemia might be related to a good prognosis. According to Robbins et al., a negative or positive FDG-PET result allows for allocation of a particular patient to a low-risk or a high-risk group of DTC-related death (25) . However, the authors also included DTC patients with clinically overt metastases into the study group, where the lack of FDG uptake in cancer foci is related to lower DTC aggressiveness and simultaneously to the slower DTC progression. Regarding our group of DTC patients without clinically apparent metastases, the lack of FDG uptake did not unequivocally exclude the presence of aggressive metastases still too small to be detected. Our data did not indicate unequivocal relationship between the negative result of FDG-PET and favourable DTC course. We did not evaluate the overall survival because all study participants were alive at the end of follow-up. We were not able to compare the eventfree survival (EFS) depending on FDG-PET result either. In FDG-PET, the detection of a cancer lesion, leading to an increase in Tg level, was equal to DCT progression (EFS = 0). The follow-up for at least 4 years of a group of 42 DTC patients with a negative FDG-PET result showed that DTC progression was diagnosed in most of them. Thus, negative FDG-PET in such patients does not guarantee a long-term asymptomatic DTC course. In our study, a longterm event-free survival, at least 4 years, was observed in 33% of FDG-negative patients only. These data may change after a longer period if we are able to evaluate the character of multiple small lung nodules noticed in nearly every third patient. DTC progression and new DTC foci were found in subsequent imaging studies in 40% of patients. Most often, local recurrences, detected by neck US and confirmed by FNAB, were observed. Noteworthy, in four patients, DTC foci were localized by subsequent FDG-PET, performed 1-3 years later. This observation not only emphasizes the important role of FDG-PET in diagnostics of asymptomatic hyperthyroglobulinemia but also underlines the significance of conditions under which FDG-PET is carried out and their impact on its sensitivity. We believe that FDG-PET done under TSH stimulation is related to its increased sensitivity. Moreover, the use of an appropriate Tg cut-off level may additionally improve it. On the other hand, our analysis indicates that FDG-PET might be carried out in patients with lower than required serum Tg level, especially when its growth is noticed during the follow-up. Based on the follow-up of a group of DTC patients in whom the first FDG-PET did not localize the source of hyperthyroglobulinemia, we demonstrated that a negative FDG-PET did not guarantee a long-term progression-free survival and did not justify any less strict DTC monitoring. A negative result of the first FDG-PET did not constitute any contraindication to repeat this examination, especially when further increase in serum Tg level was observed. The use of TSH stimulation showed a beneficial effect on the quality of FDG-PET, particularly when rhTSH may be administered, demonstrating a comparable efficacy to endogenous stimulation without an unfavorable impact on quality of life. The small number of our group, additionally divided regarding Tg serum concentration and hormonal condition, is the essential limitation of our study. However, considering the fact that DTC is a rare neoplasm, other studies involving even a smaller number of patients are commonly published (9, 22, 23, 24) . On the other hand, long follow-up constitutes the most important value of our analysis, crucial in a case of DTC characterized by a long-term disease course. The authors plan the reassessment of the whole group, particularly in patients with small lung nodules. If a long-standing DTC remission is obtained, it will allow for a better evaluation of the prognostic value of a negative FDG-PET result in patients with asymptomatic hyperthyroglobulinemia.
Conclusions FDG-PET in DTC patients with asymptomatic hyperthyroglobulinemia constitutes a valuable diagnostic tool, particularly when it is performed under optimal conditions. However, widely accepted Tg cut-off values do not always find a confirmation in a daily practice. Negative FDG-PET demonstrated a limited prognostic significance, as only every third patient did not show DTC progression for a median 5-year period. Moreover, negative FDG-PET does not justify less strict DTC monitoring, because it is related to 40% risk of relapse during 5-year follow-up.
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